Andes pediatrica : revista Chilena de pediatria · 2025
[Incidence, evolution and clinical behavior of pseudocholelithiasis associated with ceftriaxone in children].
СтатьяНаблюдательное исследованиеАннотация на английскомНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rodríguez Rangel Diego Andrés, Arenas Camacho Laura Daniela, Quiroga Barrera Nicolas Andres, Lizarazo Angie Daniela, Navas Casas Zully Marley, Ferreira Traslavifta Hugo, Uribe Caputi Juan Carlos
Аннотация
UNLABELLED: Ceftriaxone-associated pseudocholelithiasis is common but underdiagnosed in children, occurring in up to half of those receiving ceftriaxone. Although self-limiting, it is frequently accompanied by symptoms.
OBJECTIVE: To report the incidence, course, risk factors, and clinical behavior of pseudocholelithiasis in children receiving ceftriaxone.
PATIENTS AND METHOD: Prospective, descriptive, observational case series study. Patients aged 1 month to 18 years who received ceftriaxone were included. Clinical follow-up and hepatobiliary ultrasound were performed at the start of treatment and every 5 days until complete resolution. Association with risk factors was explored. Statistics used included Pearson's chi-square test and Fisher's exact test.
RESULTS: Eighty patients were included, 51.2% were male, median age 4.5 years (range 5 months to 17 years). The prevalence of pseudocholelithiasis was 35% (28 patients), documented in 6 and 27 patients during the first and second ultrasound (21.4% and 96.4%). Pseudocholelithiasis was significantly more frequent in the age group older than 5 years, those with lower fluid intake, obese, overweight, and very rare in malnourished patients (all p < 0.05). Twelve patients presented abdominal pain as a cardinal symptom (42.9%). The mean duration of the stones was 19.1 (5-44) days.
CONCLUSION: Ceftriaxone-associated pseudocholelithiasis is common, occurring in 1 out of 3 children who receive it. Its main risk factors were age over 5 years, lower fluid intake, overweight, and obesity. Abdominal pain is frequent, and the progression was self-limited.
OBJECTIVE: To report the incidence, course, risk factors, and clinical behavior of pseudocholelithiasis in children receiving ceftriaxone.
PATIENTS AND METHOD: Prospective, descriptive, observational case series study. Patients aged 1 month to 18 years who received ceftriaxone were included. Clinical follow-up and hepatobiliary ultrasound were performed at the start of treatment and every 5 days until complete resolution. Association with risk factors was explored. Statistics used included Pearson's chi-square test and Fisher's exact test.
RESULTS: Eighty patients were included, 51.2% were male, median age 4.5 years (range 5 months to 17 years). The prevalence of pseudocholelithiasis was 35% (28 patients), documented in 6 and 27 patients during the first and second ultrasound (21.4% and 96.4%). Pseudocholelithiasis was significantly more frequent in the age group older than 5 years, those with lower fluid intake, obese, overweight, and very rare in malnourished patients (all p < 0.05). Twelve patients presented abdominal pain as a cardinal symptom (42.9%). The mean duration of the stones was 19.1 (5-44) days.
CONCLUSION: Ceftriaxone-associated pseudocholelithiasis is common, occurring in 1 out of 3 children who receive it. Its main risk factors were age over 5 years, lower fluid intake, overweight, and obesity. Abdominal pain is frequent, and the progression was self-limited.